Dapsone and Type iv hypersensitivity reaction - a phase IV clinical study of FDA data

Summary:

Type iv hypersensitivity reaction is reported as a side effect among people who take Dapsone (dapsone), especially for people who are female, 60+ old, also take Lamprene, and have Leprosy.

The phase IV clinical study analyzes which people have Type iv hypersensitivity reaction when taking Dapsone. It is created by eHealthMe based on reports of 11,499 people who have side effects when taking Dapsone from the FDA, and is updated regularly.

What is Dapsone?

Dapsone has active ingredients of dapsone. It is often used in dermatitis herpetiformis. eHealthMe is studying from 11,732 Dapsone users. Check the latest studies of Dapsone.

What is Type iv hypersensitivity reaction?

Type iv hypersensitivity reaction (delayed type hypersensitivity as the reaction takes two to three days to develop) is found to be associated with 194 drugs and 415 conditions by eHealthMe. Check the latest studies of Type iv hypersensitivity reaction.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

11,499 people reported to have side effects when taking Dapsone.
Among them, 11 people (0.1%) have Type iv hypersensitivity reaction.

Could Dapsone cause Type iv hypersensitivity reaction?

Among these 11 people:

What is the gender of people who have Type iv hypersensitivity reaction when taking Dapsone? *

female: 54.55 %
male: 45.45 %

What is the age of people who have Type iv hypersensitivity reaction when taking Dapsone? *

What are other drugs people take besides Dapsone? *

What are other side effects people have besides Type iv hypersensitivity reaction? *

Rashes (redness): 6 people, 54.55%
Granuloma (a small area of inflammation due to tissue injury): 4 people, 36.36%
Tuberculoid Leprosy (a skin condition characterized by solitary skin lesions that are asymmetrically distributed): 4 people, 36.36%
Skin Plaque (red, scaly patches to appear on the skin): 3 people, 27.27%
Pain In Extremity: 2 people, 18.18%
Pain Of Skin: 2 people, 18.18%
Neuropathy Peripheral (surface nerve damage): 2 people, 18.18%
Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it): 2 people, 18.18%
Skin Induration (an abnormally hard spot or area on the skin): 2 people, 18.18%
Pain: 1 person, 9.09%

What are the existing conditions these people have? *

Leprosy (a disfiguring disease caused by the mycobacterium leprae bacteria): 7 people, 63.64%
Lymphadenitis (inflammation or enlargement of a lymph node): 1 person, 9.09%
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 1 person, 9.09%
Disease Progression: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Dapsone and have Type iv hypersensitivity reaction?

- Check whether Type iv hypersensitivity reaction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dapsone:

Dapsone (11,732 reports)

Browse all side effects of Dapsone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Type iv hypersensitivity reaction:

Type iv hypersensitivity reaction (194 drugs)

Browse all the conditions that are associated with Type iv hypersensitivity reaction:

Type iv hypersensitivity reaction (415 conditions)

Related publications that referenced our studies

Semira ZA, Zulfkar Q, Sameem F, "Livedo reticularis associated with dapsone therapy in a patient with chronic urticaria", Indian journal of pharmacology, 2014 Jan .
Semira ZA, Zulfkar Q, Sameem F, "Livedo reticularis associated with dapsone therapy in a patient with chronic urticaria", Indian journal of pharmacology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on dapsone (the active ingredients of Dapsone) and Dapsone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.